Since April 2017, the European Pharmacopeia allows to produce Water for Injection (WFI) using other methods than distillation. Meanwhile, the additional water quality "Highly Purified Water" (HPW) could be found in the Ph. Eur. but will be removed in April 2019. This means a huge change in the regulatory situation for the pharmaceutical companies. A new Q&A document had been launched by the EMA, but some topics remain unclear. Therefore, the ISPE D/A/CH CoP water and steam has discussed all questions extensively for 1.5 years and written down their position.
This webinar provided insight into the thoughts of the ISPE D/A/CH experts and additionally addresses the following questions:
Listen to Fritz Röder and a team of panelist as they discuss ten of the most asked or most interesting questions from the webinar in April 2019.
Fritz Roeder of Merck is based in Darmstadt, Germany and is an experienced project manager and engineer with broad knowledge in the pharmaceutical industry. He is an experienced speaker and author on a variety of pharmaceutical water topics.
Michael Clever of Roche is based in Penzberg, Germany and is an expert in the field of clean media operations with a strong engineering background in utility plants. He did a lot of research in the field of ultrafiltration and rouging.
Jochen Schmidt based in Basel, Switzerland, is the Process Utilities Lead at CRB. He has been working in the pharmaceutical water sector for more than 20 years with his main focus on the conception, process selection and dimensioning of complete water systems for the generation, storage and distribution of PW, WFI and pure steam.
Did you miss the webinar? Listen to the Water for Injection Using Non-Distillative Methods Webinar. Not a Member of ISPE? Join ISPE to gain access to all of our past webinars – and check out the webinar page to see all of the topics that have been discussed and what’s coming up.
As with all aspects of our life sciences industry, understanding how we can best meet the needs of patients with the timely delivery of life saving and sustaining products is of paramount concern. During the years since the global pandemic, the expectations and pressures on the pharmaceutical industry with respect to development, speed to market, quality and sustainability have increased...
At the 2024 ISPE Europe Annual Conference, held in Lisbon, Portugal, 16-18 April, Richard L. Friedman, MS, Deputy Director of the US Food and Drug Administration’s (US FDA) Office of Manufacturing Quality, in...
Insight from Austria’s Regulatory Authority Representative
At the 2024 ISPE Aseptic Conference, held March 12-13 in Vienna, Austria, Christina Meissner, a European Union Good Manufacturing Practice (GMP) inspector at the Austrian Agency for Health and Food Safety since 2013, and Chair of the PIC/S Drafting Group on Annex 2A and 2B, published in May 2021, offered a presentation titled...